Public Consultation on the Post-market Review of Ezetimibe
Page last updated: 20 December 2017
Accessibility
The documents on this page may not be accessible. If you need assistance please email the Ezetimibe Review Secretariat.
Draft Review Reports
The call for submissions addressing the draft Report for the Post-market Review of Ezetimibe closed on 10 February 2017 and addressing the revised draft Report closed on 6 June 2017. The Department appreciates the contribution of all stakeholders who made a submission.
The Final Report and stakeholder submissions were submitted to the PBAC for consideration at the July 2017 PBAC Meeting.
Stakeholder Forum
A targeted Stakeholder Forum was held in Canberra on Friday 11 November 2016.
The Call for Submissions addressing the Stakeholder Forum Outcome Statement closed on 25 November 2016.
- Stakeholder Forum Outcome Statement - (PDF 343 KB)
- Stakeholder Forum Outcome Statement - (Word 724 KB)
The Department appreciates the contribution of all stakeholders who made a submission.
Public Submissions addressing the Terms of Reference
The Call for Submissions addressing the Terms of Reference closed on 22 April 2016. The Department appreciates the contribution of all stakeholders who made a submission.
Public Submissions on the draft Terms of Reference
The Call for Submissions on the draft Terms of Reference closed on 13 November 2015. The Department appreciates the contribution of all stakeholders who made a submission.
Disclaimer
- The views expressed in submissions published on this website are solely those of the contributing authors or organisations.
- The Commonwealth accepts no responsibility for the completeness or accuracy of any information contained in the submissions.
- The Commonwealth makes no representations about the suitability of the information for any particular purpose. Users of the information must make their own inquiries and assessments about those matters or seek independent advice.
- Submissions are published on the understanding that the contributing authors or organisations have copyright in the submissions either by way of ownership or a licence. They retain their copyright, and by making submissions they licence the Commonwealth to publish the submissions, unless a party when making a submission has requested that it be kept confidential and the Commonwealth clearly agrees that the submission will be kept confidential.
Privacy
Unless otherwise requested, submissions addressing the Post-market Review of Ezetimibe have been published below.
The Department of Health does not publish submissions, or parts of submissions, which contain personal information, offensive language, potentially defamatory material or copyright infringing material.
Responsibility for copyright in submissions resides with the author(s), not with the Department of Health.
All submissions have been converted to Portable Document Format (PDF) for publication and may have a different appearance to the document that was submitted.
Your submission and contact details will be stored in accordance with the Australian Privacy Principles from Schedule 1 of the Privacy Act 1988 and the Archives Act 1983. Should you have any concerns about the storage of your submission, or if you wish to gain access to make a correction, please contact the Ezetimibe Review Secretariat. A copy of the Department’s privacy policy is available on request. If you wish to make a complaint about the handling of your private information, you may contact the Department of Health Privacy Contact Officer and, if unsatisfied with the response, you may submit a complaint to the Office of the Australian Information Commissioner.
Table of Submissions addressing the Stakeholder Forum Outcome Statement
|
Submission |
Author Name |
Document Link |
Date Received |
|---|---|---|---|
|
1 |
The Pharmacy Guild of Australia |
23/11/2016 |
|
|
2 |
Professor Paul Nestel, Alfred Hospital Melbourne |
25/11/2016 |
|
|
3 |
Professor David Hare, University of Melbourne |
25/11/2016 |
|
|
4 |
Research Organisation |
Not for publication |
25/11/2016 |
|
5 |
MSD |
25/11/2016 |
|
|
6 |
Industry Organisation |
Not for publication |
01/12/2016 |
Table of Submissions addressing the Terms of Reference
|
Submission |
Author Name |
Document Link |
Date Received |
|---|---|---|---|
|
1 |
Council of Australian Therapeutic Advisory Groups (CATAG) |
20/04/2016 |
|
|
2 |
Assoc. Prof. John Amerena |
21/04/2016 |
|
|
3 |
Amgen Australia Pty Ltd |
22/04/2016 |
|
|
4 |
Sanofi |
22/04/2016 |
|
|
5 |
Merck Sharp & Dohme (Australia) Pty Limited |
22/04/2016 |
|
|
6 |
Medicines Australia |
22/04/2016 |
Table of Submissions addressing the draft Terms of Reference
|
Submission |
Author Name |
Document Link |
Date Received |
|---|---|---|---|
|
1 |
Academic/ Health professional |
Not for publication |
30/10/2015 |
|
2 |
Prof. Paul Nestel |
5/11/2015 |
|
|
3 |
Academic/ Health professional |
Not for publication |
5/11/2015 |
|
4 |
Merck Sharpe & Dohme (Australia) Pty Limited |
13/11/2015 |
|
|
5 |
Medicines Australia |
13/11/2015 |
|
|
6 |
Kidney Health Australia |
16/11/2015 |
